Economic Implications of Treatment-Resistant Depression Among Employees
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Conservative estimates indicate between 10% and 20% of all individuals with major depressive disorders (MDDs) fail to respond to conventional antidepressant therapies. Amongst those with MDD, individuals with treatment-resistant depression (TRD) have been found to be frequent users of healthcare services and to incur significantly greater costs than those without TRD. Given the prevalence of the disorder, it is understandable that MDDs are responsible for a significant amount of both direct and indirect healthcare costs. Objective To provide empirical findings for employees likely to have TRD based on analysis of employer claims data, in the context of previous research. Methods We conducted a claims data analysis of employees of a large national (US) employer. The data source consisted of medical, pharmaceutical and disability claims from a Fortune 100 manufacturer for the years 1996-1998 (total beneficiaries >100000). The employee sample included individuals with medical or disability claims for MDDs (n = 1692). A treatment pattern algorithm was applied to classify MDD patients into TRD-likely (n = 180) and TRD-unlikely groups. Treated prevalence of select comorbid conditions and the patient costs (direct and indirect) from the employer perspective by condition were compared among TRD-likely and TRD-unlikely employees, and with a 10% random sample of the overall employee population for 1998. Results The average annual cost of employees considered TRD-likely was d…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous research indicated that depression has a significant economic impact on medical care costs [19] and worker productivity [20]”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
(1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974
Self-citationDistributed Disturbances in Brain Structure and Function in Schizophrenia
(2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 969
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
(2001) · PubMed · Cited by 780
Social Functioning in Depression: A Review
Hirschfeld, R. M. A., Montgomery, S. A., Keller, M. B., Kasper, S., Schatzberg, A. F., Moller, H.-J., Healy, D., Baldwin, D., Humble, M., Versiani, M., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0405 · Cited by 586
Research works printed but not linked: 8
- Greenberg, 1993, J Clin Psychiatry, 54, 405
- 2000, Am J Psychiatry, 157, 1
- Mitchell, 1997, Am J Manag Care, 3, 323
- Thompson, 1996, Am J Manag Care, 2, 1239
- Sclar, 1994, Clin Ther, 16, 715
- Browne, 1998, Drug Benefit Trends, 33-, 42
- Burton, 1998, Dis Manag Health Outcomes, 2, 17
- Barnett, 2000, Am J Manag Care, 6, 1243
Cited by
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
“By and large, treatment-resistant depression is associated with extensive use of depressionspecific and general medical services, which poses a substantial economic burden, together with work loss costs.(27,28) In a related context, a randomized, controlled trial evaluated the incremental cost-effectiveness over 24 we…”
What Does Research Tell Us About Depression, Job Performance, and Work Productivity?
Lerner, D., & Henke, R. M. (2008) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e31816bae50 · Cited by 509
Birnbaum, H. G., Kessler, R. C., Kelley, D., Ben-Hamadi, R., Joish, V. N., & Greenberg, P. E. (2010) · Depression and Anxiety · doi:10.1002/da.20580 · Cited by 380
“In particular, depressed patients who do not respond to treatment have more than twice the resource use and costs of patients who are not treatmentresistant as well as higher indirect costs.([8,10]) However, the literature on costs of severe MDD that categorize patients using actual clinical measures is sparse.”
BackgroundSelf-citationJohnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Priority medicines for Europe and the world
Kaplan, W. A., Laing, R. O., & Neal, B. C. (2004) · Cited by 248
Metadata
- Authors
- Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A.
- Affiliations
- Analysis Group (United States) (US)
- Pharmaceutical Product Development (United States) (US)
- Corresponding author
- Greenberg, Paul
- Venue
- PharmacoEconomics
- Published
- 2004
- Volume
- 22
- Issue
- 6
- Pages
- 363-373
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W1971622512
- Cited by
- 113
- References
- 32
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 9 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 2 · 2013: 10 · 2012: 8
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, health care costs, work loss costs, comorbidities, disability claims
- MeSH terms
- Adult, Aged, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, Health Benefit Plans, Employee, Humans, Male, Middle Aged, United States, Comorbidity, Prevalence, Treatment Failure, Economics, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic Implications of Treatment-Resistant Depression Among Employees. https://app.cochat.ai/papers/10.2165/00019053-200422060-00003
- The paper
- Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A. (2004). Economic Implications of Treatment-Resistant Depression Among Employees. PharmacoEconomics. https://doi.org/10.2165/00019053-200422060-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.